



BIOCOVAX™

VACCINE FOR COVID-19

ORAL POLIO VACCINE FOR COVID-19

BioCovax is a FDA approved oral polio vaccine which can be used in combination therapy with other drugs and vaccine for the prophylaxis and treatment of Covid-19.

SAFETY

An oral polio vaccine was approved by the FDA in 1960s, and has been used successfully to eradicate polio in more than 100 countries for over 50 years.

EFFICACY

BioCovax provided an immediate and emergency response from the innate immune system against Covid-19 with 98% effectiveness.



HOW DOES IT WORK?

- Poliovirus and coronavirus are positive-strand RNA viruses; they may induce and be affected by common innate immunity mechanisms
- BioCovax has undergone clinical studies to show that it can provide an immediate and emergency response from the innate immune system against Covid-19
- BioCovax can be used in a combination therapy with other drugs and vaccines to protect patients from Covid-19 infections. Example, BioCovax can be used in conjunction with Traneurocin, a neuroprotection drug to protect people from potential side effects of Vaccine-associated paralytic poliomyelitis

BIOCOVAX

- BioCovax contains only Type 1 and 3 strains, with no type 2 strains (Bivalent)
- More effective and safer than Trivalent OPV
- Recommended for Routine Immunization Activities (RIAs)

Biomed Industries, Inc.

San Jose, CA 95131 USA

www.biomedind.com

Info@biomedind.com

BIVALENT POLIOMYELITIS VACCINE TYPE 1 & 3, LIVE (ORAL)

DESCRIPTION

•BioCovax B1/3 contains suspension of live attenuated poliomyelitis type 1 and type 3 viruses (Sabin strain) prepared in Primary Monkey Kidney Cells. Each dose contains the following:

BIOCOVARTM Polio Vaccine 1/3

Stabilized with MgCl₂, 1 M

One dose ~0.10 ml (2 drops) contains:

Poliomyelitis Type 1 (Sabin strain)	NLT 10 ^{6.0} CCID ₅₀
Poliomyelitis Type 3 (Sabin strain)	NLT 10 ^{5.8} CCID ₅₀
Kanamycin Sulphate USP	0.15 µg
and Neomycin Sulphate USP	0.15 µg
Water for injection USP	0.10 ml

ADMINISTRATION

BioCovax B1/3 must be administered only orally. Two drops are delivered directly into the mouth of the vaccinee from the multi-dose vial by dropper or dispenser. Care should be taken not to contaminate the multi-dose dropper with saliva of the vaccinee. Once opened, multi-dose vials should be kept between +2° and +8 degree C. The vaccine is approved for use for up to 28 days after opening of the vial, as determined by WHO.

ADVERSE EFFECTS

Millions of Oral Polio Vaccine doses have been dispensed worldwide, and no major adverse effects have been observed, except for vaccine-associated paralysis (one case per 1 million doses administered). Traneurocin is recommended to be administered in conjunction with BioCovax to mitigate the risks of vaccine-associated paralytic poliomyelitis.

CONTRAINDICATIONS

BioCova B1/3 is contraindicated in those with primary immune deficiency disease or suppressed immune response from medication, leukemia, lymphoma or generalized malignancy.

STORAGE

The recommended storage temperature for BioCovax B1/3 is at -20 degree C or below until the expiry date indicated on the vial. It can be stored at + 2 degree C and +8 degree C at any time during the shelf-life until the expiry date.



Biomed Industries, Inc.
San Jose, CA 95131 USA
www.biomedind.com